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Abstract
Objective: We aimed to test the association between age, BMI and sex-hormone–binding 
globulin (SHBG) in a homogenous cohort of white-European men presenting for primary 
couple’s infertility.
Design: Retrospective study.
Methods: Data from 1547 infertile men were analysed. Health-significant comorbidities 
were scored with the Charlson comorbidity index (CCI). Fasting serum hormones were 
measured in every patient. Age was considered according to quartile groups (<33, 33-41, 
>41 years) and BMI as normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2) 
and obesity (>30 kg/m2). Descriptive statistics and linear regression analysis tested the 
associations between age, BMI and SHBG.
Results: Median SHBG levels increased across quartiles of age and decreased along with 
BMI increases (all P < 0.001). For each year increase in age, SHBG increased  
0.32 nmol/L; conversely, for each unit increase in BMI, SHBG decreased by 1.1 nmol/L  
(all P < 0.001). SHBG levels decline with increasing BMI was greater than SHBG 
progressive increase with age. Overall, BMI explained 3.0 times more of the variability 
in SHBG than did ageing. At multivariate linear model, age and BMI were the most 
significant factors influencing SHBG concentration (all P < 0.001), after accounting for CCI, 
albumin levels and smoking status.
Conclusions: We found a wide distribution of SHBG concentrations across age and BMI 
values in primary infertile men. The association between BMI and lowered SHBG levels 
seems to be greater than the association of ageing with increased SHBG.
Introduction
In postpuberal males the testes contribute to more 
than 95% of total testosterone (tT) in serum, where 
it equilibrates between protein-bound (98%) and free 
hormone (1–2%) fractions (1). Circulating testosterone is 
bound either to low-affinity proteins (primarily albumin 
but also transcortin and orosomucoid) or to the high-
affinity glycoprotein sex-hormone-binding globulin 
(SHBG) (2). These binding proteins have potential clinical 
relevance since they influence both tissue bioavailability 
and metabolic clearance rate of testosterone, while 
regulating the amount of free testosterone (fT) available 
for eventual biological actions in the tissues (1, 2). The 
tight SHBG-testosterone binding renders testosterone 
fraction biologically inactive, as testosterone is unable 
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to diffuse through cell membranes when bound to 
SHBG, while contributing to the major proportion of tT 
measured, that is, the standard test to identify men with 
testosterone deficiency (2, 3, 4). Therefore, variations in 
SHBG concentration may have a considerable impact on 
tT deficiency diagnosis in clinical practice (1, 2).
Despite most of current scientific guidelines suggest 
measuring fT only in patients with borderline tT and if 
there is concern that the patient may have altered SHBG 
concentrations (4, 5), the importance of calculated fT 
(cFT) and SHBG over tT alone in assessing symptoms of 
androgen deficiency in men with sexual dysfunctions 
has been recently outlined (3, 6). Similarly, Ring et  al. 
investigated the clinical utility of testing SHBG/cFT values 
in infertile men (7).
Several factors are known to influence serum SHBG 
levels such as ageing, obesity, diabetes mellitus (DM), 
thyroid diseases and cirrhosis (8, 9, 10). Of relevance, 
SHBG was found to linearly increase with ageing 
while decreasing with increasing BMI values (8, 9, 11). 
Additionally, SHBG per se has also been shown to be an 
independent determinant of DM, metabolic syndrome 
(MetS), cardiovascular diseases (CVD) and overall mortality 
risk (12, 13, 14). Overall, all these latter conditions have 
been observed to be highly prevalent in men with male 
factor infertility (MFI) (15, 16, 17, 18).
As a whole, there is limited information regarding 
the variability of serum SHBG distributions in clinical 
populations of men in whom SHBG concentrations may 
impact medical decision-making, such as throughout the 
work-up of men with MFI.
These observations prompted us to retrospectively 
investigate the distribution of serum SHBG in a 
homogeneous cohort of white-European men presenting 
for primary couple’s infertility in the real-life setting, with 
a specific focused analysis dedicated to the relationship 
between SHBG levels, age and BMI.
Materials and methods
In this retrospective study, we analysed data from 1547 
consecutive white-European men assessed at a single 
academic centre for couple’s primary infertility between 
September 2014 and August 2019. Patients were enrolled 
if they were ≥18 and ≤60 years old and had MFI only. MFI 
was defined after a comprehensive diagnostic evaluation 
of all the female partners carried out by expert infertility-
trained gynaecologists. According to the World Health 
Organization (WHO) criteria, infertility was defined as 
not conceiving a pregnancy after at least 12 months of 
unprotected intercourses regardless of whether or not a 
pregnancy ultimately occurs (19). Primary infertility was 
defined when a couple was never able to conceive (19).
Patients were assessed with a thorough self-reported 
medical history including age and comorbidities. The 
Charlson comorbidity index (CCI) was applied to 
score health-significant comorbidities, coded using the 
International Classification of Diseases, 9th revision 
(20). Likewise, BMI was calculated for each patient 
and categorized according to the NIH definitions of 
‘normal’ (below 24.9 kg/m2), ‘overweight’ (from 25 to 
29.9) and ‘obese’ (30+) (21). Testes volume was assessed 
using a Prader orchidometer (22) by a single expert uro-
andrologist, calculating the mean value between the two 
sides. Smoking habit was investigated according to the 
pack-year history and then categorized in two groups 
as follows: no smokers (never and former smokers) or 
current smokers (23).
Varicocele was clinically assessed in every patient and 
further confirmed by ultrasound examination (24).
Venous blood samples were drawn from each patient 
between 07:00 h and 11:00 h after an overnight fast 
(1). Follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) were measured using a heterogeneous 
competitive magnetic separation assay (Bayer Immuno 
1 System, Bayer Corp.). Inhibin B (InhB) was measured 
by an ELISA (Beckman Coulter AMH Gen II ELISA). Total 
testosterone was measured via a direct chemiluminescence 
immunoassay (ADVIA Centaur; Siemens Medical 
Solutions Diagnostics) and SHBG levels were measured 
via a solid-phase chemiluminescent immunometric assay 
on Immulite 2000 (Medical Systems SpA, Genoa, Italy). 
Serum albumin and SHBG values were measured and 
utilized to determine cFT using the validated Vermeulen 
formula (25). Chromosomal analysis and genetic testing 
were performed in every patient (karyotype analysis and 
tests for Y-chromosome microdeletions and cystic fibrosis 
mutations) (26). The same laboratory was used for the 
analysis of all parameters for all patients.
Patients underwent at least two consecutive semen 
analyses, both showing below standard values for normal 
semen parameters according to the WHO criteria (27). For 
the specific purposes of this analysis, we considered semen 
volume, sperm concentration, progressive sperm motility 
and normal morphology. Sperm DNA fragmentation 
index (SDF) was measured by sperm chromatin structure 
assay (SCSA) in every patient (28).
Men with genetic abnormalities (any type) were 
excluded from final analysis; likewise, patients who had 
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testicular or pituitary surgery and/or previous vasectomy 
and men who were on pharmacological agents (any) that 
could affect tT values (i.e. clomiphene citrate) at the time 
of investigation were removed from the final analysis. No 
cases of liver cirrhosis or chronic use of steroids that could 
have an influence on SHBG values have been found.
Data collection followed the principles outlined 
in the Declaration of Helsinki. All patients signed an 
informed consent agreeing to share their own anonymous 
information for future studies. The study was approved by 
the IRCCS San Raffaele Hospital Ethical Committee (Prot. 
2014 – Pazienti Ambulatoriali).
Statistical methods
Distribution of data was tested with the Shapiro–Wilk test. 
Data are presented as medians (interquartile range; IQR) or 
frequencies (proportions). A 95% CI was estimated for the 
association of categorical parameters. First, demographics 
characteristics, hormonal values and semen parameters 
were compared among patients as segregated according 
to quartiles of age (namely, <33 years, 33–40 years, and 
≥41 years) with the Kruskal–Wallis test and the Chi-square 
test. Similarly, descriptive statistic was applied to the 
whole cohort as segregated according to BMI categories 
(21). To explore the effects of age and BMI on SHBG, men 
were divided into four groups (9): (1) nonobese younger, 
(BMI <30 and age <37); (2) obese younger (BMI ≥30 and 
age <37); (3) nonobese older (BMI <30 and age ≥37); 
and (4) obese older men (BMI ≥30 and age ≥37). SHBG 
among groups was compared with Kruskal–Wallis test 
with multiple comparisons. Subsequently, we graphically 
explored the relationship between SHBG with age and 
BMI using the locally weighted scatterplot smoothing 
(LOWESS) method to account for possible non-linear 
relationships (29). Finally, univariable (UVA) and 
multivariable (MVA) linear regression analyses tested the 
associations between clinical variables (e.g. age, BMI, CCI, 
albumin and smoking habits) and SHBG values. Statistical 
analyses were performed using SPSS v.26 (IBM Corp.) 
and Stata 14.0 (StataCorp, College Station, TX, USA). All 
tests were two sided, and statistical significance level was 
determined at P < 0.05.
Results
Table 1 lists descriptive statistics of the entire cohort of 
patients as segregated according to quartiles of age at 
first assessment. Patients’ BMI and CCI increased among 
quartiles of age (all P ≤ 0.03). Total testosterone (P = 0.03) 
and cFT (P < 0.001) decreased with age; on the contrary, 
SHBG increased across quartiles of age (P < 0.001). Table 2 
lists descriptive statistics of the entire cohort of patients 
as segregated according to BMI groups. Accordingly, 
median tT, cFT and SHBG values decreased across BMI 
groups (P < 0.001) (Table 2). In terms of semen parameters, 
both sperm concentration and sperm motility decreased 
across age and BMI groups (all P ≤ 0.04); conversely, SDF 
increased with age and BMI increases (Tables 1 and 2).
Figure 1 shows SHBG distribution among patients 
subcategorized in groups by age and BMI. As depicted, 
SHBG values changed across the four groups (P < 0.001), 
with lowest SHBG value being observed in obese-younger 
men (19.9 (15-23); P < 0.01 vs all groups), while the highest 
value being observed in nonobese-older men (33 (25-43); 
P < 0.01 vs all groups) (Fig. 1).
Figure 2 shows the LOWESS curves depicting the 
association between SHBG with age and BMI. In this 
context, a negative linear correlation was found between 
SHBG and BMI (P < 0.001); conversely, SHBG linearly 
increases with age (P < 0.001). SHBG was positively 
correlated with tT (P < 0.001) but not with cFT (P = 0.08) 
(data not shown).
At linear regression analysis, SHBG was found to 
decrease by 1.1 nmol/L (95% CI: −1.2, −0.8) for each 
unit increase in BMI; conversely, SHBG increased 0.32 
(95% CI: 0.2, 0.4) nmol/L for each year increase in age 
(P < 0.001 for both effects) (Table 3). The progressive 
decline in SHBG with increasing BMI was greater than 
the progressive increase in SHBG with age. Overall, BMI 
explained 3.0 times more of the variability in SHBG than 
did ageing (r2 = 0.06 for BMI and r2 = 0.02 for age). At 
multivariate linear model, age and BMI emerged as the 
most significant factors influencing SHBG concentration 
(all P < 0.001), after accounting for CCI, albumin levels 
and smoking status (Table 3).
Discussion
Testosterone plays a pivotal role in overall men’s health 
(1), therefore the identification and management of 
hypogonadal individuals is crucial in clinical practice. 
This is particularly relevant in patients at higher risk of 
hypogonadism and when the restoration of physiological 
testosterone levels might have important clinical and 
prognostic rebounds, such as in infertile men and in those 
with sexual dysfunction (30, 31).
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Current guidelines support the combination of clinical 
symptoms/signs and low tT values for the diagnosis of 
male hypogonadism, but they all highlight that tT could 
provide misleading information in all those conditions 
known to alter SHBG levels (4, 5). Previous studies have 
investigated the importance of SHBG testing throughout 
the evaluation of men’s gonadal status. In this context, 
Rastelli et  al. analysed data from 2622 men presenting 
for sexual dysfunction at a single centre and found that 
higher SHBG, regardless of circulating tT, was associated 
with either subjective or objective androgen deficiency 
features (3). Thereof, they stressed the clinical importance 
of SHBG testing in conjunction with tT in order to 
evaluate men with sexual dysfunction and the suspicion 
of suffering from hypogonadal status. Similarly, Ring 
et al. determined the utility of adding SHBG to standard 
tT testing for the diagnosis of male hypogonadism 
in 168 infertile men (7). Authors found that using tT 
levels alone would potentially misclassify 20–53% of 
men as eugonadal while actually being hypogonadal. 
Table 1 Descriptive statistics of the whole cohort segregated according to quartiles of age (No. = 1547).
Overall Age <33 years Age 33–40 years Age = 41 years
P-valuean = 1547 (100%) n = 287 (18.5%) n = 841 (54.3%) n = 419 (27.2%)
Age (years) 37.0 (33–41) 31.0 (29–32) 37.0 (35–38) 44.0 (42–47)
(18–60) (18–32) (33–40) (41–60)
BMI (kg/m2) 25.1 (23.3–27.2) 24.7 (22.8–27.5) 25.1 (23.3–27.2) 25.3 (23.6–27.1)b 0.03
(18.5–44.8) (18.5–39.2) (18.5–44.8) (18.5–41.4)
CCI (score) 0.0 (0–0) 0.0 (0–0) 0.0 (0–0) 0.0 (0–0)b,c <0.001
Mean (s.d.) 0.1 (0.5) 0.06 (0.3) 0.08 (0.4) 0.2 (0.7)
(0.0–8.0) (0.0–3.0) (0.0–8.0) (0.0–8.0)
CCI = 1 (No. (%)) 110 (7.1) 12 (4.2) 46 (5.5) 52 (12.4) <0.001
Type 2 DM (No. (%)) 35 (2.3) 3 (1.0) 12 (1.4) 20 (4.7) <0.01
Length of infertility (month) 21 (15–36) 18.0 (12–24) 23.0 (12–32) 24.0 (12–36) <0.001
(12.0–228.0) (12.0–168.0) (12.0–162.0) (12.0–228.0)
Testis volume 
(average Prader value) 15.0 (12–20) 15.0 (11–20) 15.0 (12–20) 15.0 (12–20) 0.1
(2.0–25.0) (2.0–25.0) (2.0–25.0) (3.0–25.0)
Smoking status (No. (%)) 0.03
Never smoked/former smokers 1100 (71.1) 186 (64.7) 605 (71.9) 309 (73.6)
Active smokers 447 (28.9) 101 (35.2) 236 (28.1) 110 (26.3)
FSH (mUI/mL) 5.5 (3.3–11.0) 5.2 (3.2–11.7) 5.2 (3.2–11.0) 5.7 (3.4–10.9) 0.14
(0.1–99.1) (1.1–74.0) (0.1–99.1) (0.1–64.7)
LH (mUI/mL) 4.2 (2.9–5.9) 4.5 (3.3–6.3) 4.1 (2.8–5.9) 4.2 (2.7–5.8) 0.3
(0.1–77.0) (1.1–35.3) (0.1–77.0) (0.1–27.0)
tT (ng/mL) 4.6 (3.4–5.7) 4.6 (3.5–5.9) 4.5 (3.4–5.7) 4.2 (3.2–5.6)b 0.03
(0.2–26.4) (0.5–15.1) (0.2–26.4) (0.2–23.5)
cFT (pg/mL) 90.9 (70.4–118.0) 98.1 (76.7–130.0) 91.5 (70.3–117.0)b 85.1 (65.1–112.0)b,c <0.001
(1.1–940.0) (1.1–667.0) (2.8–688.0) (9.1–940.0)
SHBG (nmol/L) 31.0 (23–41) 27.3 (21–37) 32.0 (23–40)b 34.0 (25–44)b,c <0.001
(2.4–104.0) (7.0–79.0) (2.4–104.0) (6.0–103)
InhB (pg/mL) 105.6 (44.2–166.3) 102.9 (43.8–168.9) 108.4 (47.5–163.6) 100.5 (38.7–166.6) 0.6
(0.5–538.0) (0.5–303.0) (0.5–538.0) (0.6–521.9)
Albumin (pg/mL) 46.7 (44.7–48.7) 47.3 (45.0–48.9) 46.8 (44.9–48.6) 46.1 (44.1–48.2)b,c <0.001
(17.9–61.3) (17.9–57.1) (23.3–60.2) (22.6–61.3)
Semen volume (mL) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0)b 0.04
(1.0–16.0) (1.0–9.0) (1.0–16.0) (1.0–9.0)
Sperm concentration 13.8 (3.2–37.0) 14.0 (3.6–34) 13.0 (3.0–39.1) 11.0 (2.9–40.0)b 0.03
(×106/mL) (0.1–455.0) (0.1–455.0) (0.1–198.4) (0.1–305.0)
Progressive motility (%) 20.0 (8.0–36.0) 24.0 (6.0–40.0) 21.0 (8–35) 16.0 (8.0–34.0)b 0.02
(0.0–84.0) (0.0–82.0) (0.0–78.0) (0.0–84.0)
Normal morphology (%) 3.0 (1.0–10.0) 2.0 (1.0–10.5) 2.0 (1.0–10.0) 2.0 (1.0–11.0) 0.4
(0.0–100.0) (0.0–80.0) (0.0–100.0) (0.0–91.0)
SDF (SCSA) (%) 35.5 (21.9–52.9) 23.5 (15.9–44.1) 35.0 (21.9–50.6) 40.8 (25.9–58.0)b,c 0.01
(0.4–99.9) (0.3–97.7) (1.4–99.8) (0.5–93.3)
Data presented as median (IQR) (range).
aP value according to the Kruskal–Wallis test, as indicated; bP < 0.05 vs Age < 33 years group; cP < 0.05 vs 33–40 years group.
CCI, Charlson comorbidity index; DM, diabetes mellitus; SDF, sperm DNA fragmentation index; tT, total testosterone.
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Conversely, 20% of patients were diagnosed with 
hypogonadism but were actually eugonadal when using 
SHBG for cFT evaluation (7). Therefore, in addition of 
standard serum tT levels, SHBG should be considered as an 
important tool during the diagnostic work-up of infertile 
men for a more accurate definition of the androgen 
milieu. Moreover, since the main peripheral organ that 
produces SHBG is the liver, which is considered the central 
metabolic organ, SHBG levels assessment is usefull in a 
more comprehensive understanding of the relevance of 
certain metabolic diseases eventually resulting in changed 
SHBG serum levels (32, 33).
It is well known that several conditions may alter serum 
SHBG concentrations (8, 9, 10, 11), with a subsequent 
impact on the actual interpretation of circulating tT 
values. However, there is limited information regarding 
the variability of serum SHBG distributions in infertile 
patients. Of relevance, infertile men per se do represent 
a critical subset of subjects, since they have been 
demonstrated to recapitulate many characteristics and 
disorders of the aging men at a significantly younger age, 
and in a relatively short time frame.
The findings of this real-life study showed that SHBG 
values significantly increase across ageing but decline 
Table 2 Descriptive statistics of the whole cohort segregated according to BMI categories (No. = 1547).
BMI 18.5–24.9 BMI 25–29.9 BMI ≥30
P-valuean = 737 (47.6%) n = 670 (43.3%) n = 140 (9.0%)
Age (years) 36.0 (33–41) 38.0 (34–41) 37.0 (34–43) <0.002
(18–60) (18–60) (23–60)
CCI (score) 0.0 (0–0) 0.0 (0–0) 0.0 (0–0) 0.2
Mean (s.d.) 0.09 (0.4) 0.1 (0.5) 0.1 (0.4)
(0.0–8.0) (0.0–8.0) (0.0–4.0)
CCI ≥ 1 (No. (%)) 43 (5.9) 42 (6.3) 12 (8.5) 0.2
Type 2 DM (No. (%)) 14 (1.9) 14 (2.1) 2 (1.4) 0.14
Length of infertility (month) 18 (12–24) 24.0 (12–36) 24.0 (15–38) <0.001
(12.0–180.0) (12.0–228.0) (12.0–204.0)
Testis volume 15.0 (12–20) 15.0 (12–20) 18.0 (11–23) 0.7
(2.0–25.0) (2.0–25.0) (2.0–25.0)
Smoking status (No. (%)) 0.1
No smokers/Former smokers 541 (73.4) 460 (68.6) 95 (67.9)
Active smokers 196 (26.6) 210 (31.4) 45 (32.1)
FSH (mUI/mL) 5.2 (3.2–10.2) 5.7 (3.4–11.0) 7.1 (3.9–12.7)b 0.02
(0.6–99.1) (0.9–74.0) (0.1–38.2)
LH (mUI/mL) 4.1 (2.9–5.9) 4.1 (2.9–5.9) 4.3 (2.7–6.3) 0.7
(0.1–35.3) (0.6–36.3) (0.8–77.0)
tT (ng/mL) 4.9 (3.8–6.1) 4.3 (3.2–5.5)b 3.3 (2.7–4.6)b,c <0.001
(0.2–23.5) (0.1–17.0) (1.1–22.5)
cFT (pg/mL) 94.8 (74.4–123.0) 89.4 (70.0–115.0)b 74.7 (59.8–102.0)b,c <0.001
(2.8–667.0) (1.1–940.0) (10.1–688.0)
SHBG (nmol/L) 35.0 (27–44) 29.0 (22–38)b 22.5 (18–31)b,c <0.001
(2.4–104.0) (7.5–95.0) (6.0–104.0)
InhB (pg/mL) 118.4 (53.7–175.3) 99.9 (40.0–163.4)b 70.0 (22.8–118.6)b,c <0.001
(0.5–465.8) (0.9–538.0) (0.5–307.6)
Albumin (pg/mL) 47.1 (45.1–48.9) 46.6 (44.8–48.5)b 45.1 (43.4–47.5)b,c <0.001
(27.1–60.2) (17.9–61.3) (26.1–52.1)
Semen volume (mL) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 0.1
(1.0–9.0) (1.0–16.0) (1.0–8.0)
Sperm concentration 18.3 (3.8–36.6) 17.0 (4.6–40.3) 10.6 (2.6–33)b 0.01
(×106/mL) (0.1–159.0) (0.1–455.0) (0.1–305.9)
Progressive motility (%) 25.0 (10.0–39.5) 24.0 (10–36) 16.0 (5.0–31.0)b 0.01
(0.0–84.0) (0.0–72.0) (0.0–82.0)
Normal morphology (%) 3.0 (1.0–10.7) 2.5 (0.0–10.0) 6.0 (1.0–14.0) 0.2
(0.0–94.0) (0.0–100.0) (0.0–85.0)
SDF (%) 33.1 (20.8–49.7) 38.0 (23.6–52.8) 38.5 (17.7–59.7)b 0.04
(1.4–97.7) (0.3–96.4) (10.0–99.8)
Data presented as median (IQR) (range).
aP value according to the Kruskal–Wallis test, as indicated; bP < 0.05 vs BMI 18.5–24.9 group; cP < 0.05 vs 25–29.9 group.
CCI, Charlson comorbidity index; DM, diabetes mellitus; SDF, sperm DNA fragmentation index; tT, total testosterone.
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according to increasing BMI categories. Of clinical 
relevance, this latter negative association observed 
between increasing BMI categories and decreased 
circulating SHBG levels, in our homogenous large cohort 
of white-European primary infertile men, was even more 
relevant than the well-known association observed with 
the ageing process (8, 9, 11).
Previous Authors have reported SHBG variability 
in men from the general population and in those with 
sexual dysfunctions. In the CARDIA Male hormone 
study, data from 474 black and 695 white men, aged 
24–31 years, have been analysed to investigate aging-
related changes in SHBG, tT and bioavailable testosterone 
according to changes in BMI (34). The authors found that 
SHBG significantly increased along with age for men, 
whose BMI decreased. Moreover, there were progressively 
smaller increases in SHBG for men whose BMI was stable 
or whose BMI increased modestly. The relationship 
between age and SHBG was lost among men whose BMI 
increased most (34). A remarkably wide distribution of 
SHBG concentrations was reported in a study with 1000 
men presenting for sexual symptoms (8). The authors 
found a nearly 20-fold difference in values over the range 
of SHBG results, with younger men having lower mean 
SHBG concentrations than older ones. Likewise, Cooper 
et al. analysed the impact of age and BMI on SHBG in 3671 
men who underwent laboratory testing for testosterone 
deficiency (9). As expected, their results showed that 
SHBG was negatively correlated with BMI but positively 
associated with age. In particular, the association between 
obesity and lowered SHBG was greater than the association 
of ageing with increased SHBG (9). Our results confirm 
those previous findings, with the further observation that 
BMI eventually impacts on SHBG distribution at a larger 
extent than age on the same parameter (namely, 3.0 times 
more). Overall, the recognition of this large variability 
of SHBG values in infertile men should be considered in 
the interpretation of androgen status in clinical practice, 
particularly in overweight and obese men, in which 
SHBG testing appears of utmost clinical importance. 
The exact mechanism underlying this association has 
not been clarified yet but reported hypothesis are the 
suppression of hepatic SHBG synthesis by elevated 
concentrations of insulin and an obesity-induced increase 
in oestrogen levels that may contributes in determining 
negative feedback at the pituitary level (35, 36, 37, 38). 
Similarly, the association of increasing age with increasing 
Figure 1
Serum SHBG distribution among patients 
subcategorized in groups by age and BMI.
Figure 2
LOWESS curves depicting the relationship between serum SHBG, age  
and BMI.
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SHBG has been demonstrated in prior studies (8, 9, 39, 
40). Data from the European Male Aging Study (EMAS) 
demonstrated a steady rise in SHBG with increasing age 
among men aged 40–70 years (40). However, the reason 
for this increase is unknown. Our study confirms a linear 
relationship between age and SHBG along with a negative 
correlation between age and BMI even in younger men, 
overall in theory at a lower risk of comorbid diseases 
than those of greater age, if they were not infertile and, 
therefore, with an epidemiologically recognized risk 
of a lower health status than the fertile counterpart 
(15, 16, 17, 18).
The clinical strength of our study is several fold. This 
study is innovative because it is the first to provide detailed 
SHBG values for a large population of men specifically 
presenting for primary couple’s infertility. Second strength 
is that we have comprehensively investigated a relatively 
large homogenous cohort of patients with a thorough 
clinical evaluation and an accurate assessment of possible 
factors that may alter SHBG values, such as recreational 
habits and health comorbidities (8). Third strength is 
SHBG measurement by a single laboratory, thus providing 
homogenous results in a specific cohort of white-European 
men presenting for primary couple’s infertility. This latter 
aspect would further provide our results with a strong 
characterization in the real-life setting.
Our study is not devoid of limitations. First, 
although these analyses have taken into consideration 
a homogenous cohort of white-European men, they 
report the findings of a single center-based retrospective 
study, thus raising the possibility of selection biases; 
thereof, larger studies across different centers and 
cohorts are needed to validate our findings. Second, our 
study did not include a control group of normal fertile 
men. Third, we did not use gas chromatography–mass 
spectrometry, which is considered the gold standard for 
measuring circulating tT levels; in contrast, to reflect 
common practice of a clinical biochemistry laboratory, 
we elected to measure circulating tT using commercially 
available analytic methods. Furthermore, serum tT levels 
were measured using a commercial assay distributed by 
a company that has modified the assay’s normal range 
throughout the time interval over which data have 
been extracted, thus leading to a potential bias and a 
consequent misinterpretation of normal ranges of the 
hormonal milieu. Lastly, fT values were calculated based 
on the validated Vermeulen formula, rather than the gold 
standards of equilibrium dialysis (41), which may have 
introduced some further bias.
Conclusions
The findings of this retrospective study revealed a 
remarkably wide distribution of SHBG concentrations 
across age and BMI in primary infertile men. The 
association between increasing BMI values and lowered 
SHBG concentrations emerged to be greater than the 
association of ageing with increased SHBG. These results 
outline the clinical importance of a probable significant 
variability in terms of SHBG concentrations in the real-life 
diagnostic and therapeutic work-up of men presenting for 
couple’s infertility, along with the concomitant suspicion 
of a relevant hypogonadism. Further large cohort studies 
are needed to corroborate our results, even in different 
ethnicity settings.
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